Human metapneumovirus (hMPV) shares symptoms with influenza and RSV, such as cough, fever, and breathing difficulties, but remains underrecognized. While most cases are mild, hMPV can lead to severe complications like viral pneumonia, acute respiratory distress syndrome (ARDS), and respiratory failure in high-risk groups.
Unlike influenza or RSV, hMPV currently has no specific antiviral treatment or vaccine available. This makes early detection through testing even more critical to managing infections and preventing severe outcomes.
It’s time to bring attention to hMPV. By prioritizing testing, we can better protect vulnerable populations and safeguard public health.
Post time: Jan-08-2025